Collaboration to enable scientists to capture known and unknown functional mutations associated with core set of pharmacokinetic and pharmacology genes LEXINGTON, Mass., and BRANFORD, Conn. – March 7, 2011 – RainDance Technologies, Inc., and 454 Life Sciences, a Roche Company, today a
Companies developing genetic screening panel targeting more than 220 known pharmacokinetic and pharmacology genes using next-generation sequencing WASHINGTON D.C., – March 7, 2011 – RainDance Technologies, Inc. and Ambry Genetics, today announced a new collaboration focused on the dev
RainDance Technologies® is making complex genetics simple. The company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers. Both technology platforms have been recognized by The Scientist as Top 10 Innovations with the RainDrop System winning the award in 2014 and the ThunderStorm System winning the award in 2011.